Epigenomics Ag Stock Price Prediction
| EPGNF Stock | USD 0.50 2.00 80.00% |
Oversold Vs Overbought
48
Oversold | Overbought |
Epigenomics AG stock price prediction is an act of determining the future value of Epigenomics shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation. The successful prediction of Epigenomics' future price could yield a significant profit. Please, note that this module is not intended to be used solely to calculate an intrinsic value of Epigenomics and does not consider all of the tangible or intangible factors available from Epigenomics' fundamental data. We analyze noise-free headlines and recent hype associated with Epigenomics AG, which may create opportunities for some arbitrage if properly timed.
It is a matter of debate whether pink sheet price prediction based on information in financial news can generate a strong buy or sell signal. We use our internally-built news screening methodology to estimate the value of Epigenomics based on different types of headlines from major news networks to social media. The Epigenomics stock price prediction module provides an analysis of price elasticity to changes in media outlook on Epigenomics over a specific investment horizon. Using Epigenomics hype-based prediction, you can estimate the value of Epigenomics AG from the perspective of Epigenomics response to recently generated media hype and the effects of current headlines on its competitors.
This module is based on analyzing investor sentiment around taking a position in Epigenomics. This speculative approach is based exclusively on the idea that markets are driven by emotions such as investor fear and greed. The fear of missing out, i.e., FOMO, can cause potential investors in Epigenomics to buy its pink sheet at a price that has no basis in reality. In that case, they are not buying Epigenomics because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell pink sheets at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Epigenomics after-hype prediction price | USD 0.5 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as pink sheet price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Epigenomics |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Epigenomics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Epigenomics After-Hype Price Prediction Density Analysis
As far as predicting the price of Epigenomics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Epigenomics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Pink Sheet prices, such as prices of Epigenomics, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Epigenomics Estimiated After-Hype Price Volatility
In the context of predicting Epigenomics' pink sheet value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Epigenomics' historical news coverage. Epigenomics' after-hype downside and upside margins for the prediction period are 0.03 and 75.50, respectively. We have considered Epigenomics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Epigenomics is out of control at this time. Analysis and calculation of next after-hype price of Epigenomics AG is based on 3 months time horizon.
Epigenomics Pink Sheet Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Epigenomics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Epigenomics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Pink Sheet price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Epigenomics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
10.32 | 73.13 | 0.00 | 18.45 | 0 Events / Month | 7 Events / Month | In a few days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
0.50 | 0.50 | 0.00 |
|
Epigenomics Hype Timeline
Epigenomics AG is currently traded for 0.50. The entity stock is not elastic to its hype. The average elasticity to hype of competition is -18.45. Epigenomics is estimated not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is insignificant. The immediate return on the next news is estimated to be very small, whereas the daily expected return is currently at 10.32%. %. The volatility of related hype on Epigenomics is about 4090.04%, with the expected price after the next announcement by competition of -17.95. About 35.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.39. Some equities with similar Price to Book (P/B) outperform the market in the long run. Epigenomics AG recorded a loss per share of 0.3. The entity had not issued any dividends in recent years. The firm had 1:4 split on the 27th of December 2022. Assuming the 90 days horizon the next estimated press release will be in a few days. Check out Epigenomics Basic Forecasting Models to cross-verify your projections.Epigenomics Related Hype Analysis
Having access to credible news sources related to Epigenomics' direct competition is more important than ever and may enhance your ability to predict Epigenomics' future price movements. Getting to know how Epigenomics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Epigenomics may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| MYNZ | Mainz Biomed BV | (0.03) | 8 per month | 0.00 | (0.06) | 6.06 | (6.25) | 33.33 | |
| APDN | Applied DNA Sciences | (0.02) | 7 per month | 0.00 | (0.17) | 5.26 | (8.33) | 29.17 | |
| STIM | Neuronetics | (0.19) | 10 per month | 3.92 | 0.05 | 11.35 | (7.31) | 31.45 | |
| PRE | Prenetics Global | (0.22) | 5 per month | 0.00 | (0.04) | 10.00 | (8.82) | 33.17 | |
| FONR | Fonar | 0.60 | 4 per month | 0.00 | (0.15) | 3.56 | (3.63) | 13.52 | |
| IQV | IQVIA Holdings | (5.22) | 10 per month | 1.13 | 0.03 | 2.22 | (1.83) | 15.51 | |
| MTD | Mettler Toledo International | (18.65) | 7 per month | 1.76 | (0.03) | 2.48 | (3.26) | 6.80 | |
| TWST | Twist Bioscience Corp | 1.95 | 10 per month | 0.00 | (0.06) | 6.34 | (5.54) | 18.88 | |
| WAT | Waters | 1.35 | 12 per month | 0.00 | (0.08) | 2.55 | (3.04) | 7.95 | |
| ICLR | ICON PLC | 2.55 | 8 per month | 1.11 | 0.09 | 2.18 | (2.08) | 12.80 |
Epigenomics Additional Predictive Modules
Most predictive techniques to examine Epigenomics price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Epigenomics using various technical indicators. When you analyze Epigenomics charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Epigenomics Predictive Indicators
The successful prediction of Epigenomics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Epigenomics AG, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Epigenomics based on analysis of Epigenomics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Epigenomics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Epigenomics's related companies. Story Coverage note for Epigenomics
The number of cover stories for Epigenomics depends on current market conditions and Epigenomics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Epigenomics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Epigenomics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Other Macroaxis Stories
Our audience includes start-ups and big corporations as well as marketing, public relation firms, and advertising agencies, including technology and finance journalists. Our platform and its news and story outlet are popular among finance students, amateur traders, self-guided investors, entrepreneurs, retirees and baby boomers, academic researchers, financial advisers, as well as professional money managers - a very diverse and influential demographic landscape united by one goal - build optimal investment portfolios
Story Categories
Currently Trending Categories
Epigenomics Short Properties
Epigenomics' future price predictability will typically decrease when Epigenomics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Epigenomics AG often depends not only on the future outlook of the potential Epigenomics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Epigenomics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 15.5 M |
Check out Epigenomics Basic Forecasting Models to cross-verify your projections. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Complementary Tools for Epigenomics Pink Sheet analysis
When running Epigenomics' price analysis, check to measure Epigenomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Epigenomics is operating at the current time. Most of Epigenomics' value examination focuses on studying past and present price action to predict the probability of Epigenomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Epigenomics' price. Additionally, you may evaluate how the addition of Epigenomics to your portfolios can decrease your overall portfolio volatility.
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |